Anthony Loera: Founder, RevGenetics

Why RevGenetics Exists

In 2006 Anthony was an engineer at one of America's largest hospice organisations, building the technology systems its healthcare workers relied on. To design them properly he rode along with hospice nurses on home visits. One visit, to a five-year-old girl with less than six months to live, is the reason the company exists.

Around the same period he and his wife were told by fertility specialists at two hospitals that they were unlikely to have children. They went on to have two. That combination, close exposure to the end of life and a personal outcome that contradicted the medical consensus, is what moved him from building software to studying how to extend healthy years.

Manufacturing, Stability and Why Expiration Dates Mislead

Two decades of buying raw materials, commissioning assays and auditing manufacturing has made shelf-life one of Anthony's principal areas of expertise. A printed expiration date is a manufacturer's assertion. It is only as good as the stability data and the manufacturing method behind it, and in the supplement category the two frequently do not match.

The clearest recurring example is liposomal delivery. A liposome is a fragile phospholipid structure, not an inert shell. Held in an aqueous suspension it is subject to oxidation and hydrolysis, the vesicles can fuse or leak, and the active it was supposed to protect can degrade or fall out of encapsulation long before the date on the bottle.

In his assessment, some liposomal products degrade meaningfully within about six months despite carrying a two-year expiration date, and certain water-containing liposomal formulations hold their actives for a window closer to three weeks to three months rather than the two years claimed. That is a manufacturing and formulation problem, not a labelling technicality, and it is the kind of thing he calls out publicly.

The practical consequence for RevGenetics is formulation choice. Where a delivery system cannot be shown to survive its own shelf life, it is not used, regardless of how well it markets.

How a Compound Becomes a RevGenetics Product

The division of labour between Anthony and Dr. Valenzuela is deliberate, and it is what keeps commercial judgement separate from scientific judgement.

1. Research and development. Anthony identifies an emerging compound and works through the published studies to judge whether the evidence is worth taking seriously.
2. Scientific review. Anything that survives that pass goes to Dr. Hector Valenzuela, Ph.D. for a full review of the mechanism, the study quality and the realistic effect size.
3. Formulation. Dr. Valenzuela advises on formulation, including dose and the delivery system the compound actually needs.
4. Manufacturing and stability. Anthony assesses whether it can be manufactured to cGMP standards and whether the formulation will hold up across a defensible shelf life.
5. Verification. Third-party assay before release, with certificates published.

A compound that fails at any stage does not ship. Interesting research is not sufficient on its own.

Scientific Review

Anthony writes on research and development, manufacturing, sourcing, formulation stability and the regulatory side of the category. Mechanistic and scientific accuracy is the responsibility of Dr. Hector Valenzuela, Ph.D., Chief Science Officer, and Fletcher Jones Chair in Molecular Biology, Department Chair and Professor of Biology at Whittier College. Dr. Valenzuela holds a Ph.D. in Experimental Pathology from UCLA and has published on immunosenescence, telomere biology and T-cell ageing.

Where an article makes a claim about a compound, the underlying study is cited. RevGenetics products are dietary supplements. They are not intended to diagnose, treat, cure or prevent any disease.